Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines

Molecular Carcinogenesis

Volumn 48, Issue 7, 2009, Pages 586-591

  Nadkarni, Aditi ^a,c   Rajesh, Preeti ^b   Ruch, Randall J ^a   Pittman, Douglas L ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Breast cancer; Cisplatin; DNA repair; Homologous recombination; p53

Indexed keywords

CISPLATIN; PIFITHRIN ALPHA; PROTEIN P53; PROTEIN RAD51D; RAD51 PROTEIN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; PRIMER DNA; RAD51L3 PROTEIN, HUMAN;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN MCF 7; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; DRUG RESISTANCE; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

MAMMALIA;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DNA PRIMERS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS;

EID: 67649227817     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20545     Document Type: Article

References (24)

1. Rodriguez-Lopez R, Osorio A, Ribas G, et al. The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutations. Int J Cancer 2004;110:845-849. (Pubitemid 38758510)
2. TarsounasM, Munoz P, Claas A, et al. Telomere maintenance requires the RAD51D recombination/repair protein. Cell 2004;117:337-347. (Pubitemid 38534540)
3. Smiraldo PG, Gruver AM, Osborn JC, Pittman DL. Extensive chromosomal instability in Rad51d-deficient mouse cells. Cancer Res 2005;65:2089-2096. (Pubitemid 40490114)
4. Gruver AM, Miller KA, Rajesh C, et al. The ATPase motif in RAD51D is required for resistance to DNA interstrand crosslinking agents and interaction with RAD51C. Mutagenesis 2005;20:433-440. (Pubitemid 41816530)
5. Nadkarni A, Furda A, Rajesh C, McInnes C, Ruch RJ, Pittman DL. Functional characterization of the RAD51D E233G genetic variant. Pharmacogenet Genomics 2009;19:153-160.
6. Altman SA, Randers L, Rao G. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog 1993;9:671-674. (Pubitemid 2022153)
7. Gary RK, Jensen DA. The p53 inhibitor pifithrin-alpha forms a sparingly soluble derivative via intramolecular cyclization under physiological conditions. Mol Pharm 2005;2:462-474. (Pubitemid 43016387)
8. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 2008;283:1026-1033.
9. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-4300. (Pubitemid 27413438)
10. Wikman FP, Lu ML, Thykjaer T, et al. Evaluation of the performance of a p53 sequencing microarray chip using 140 previously sequenced bladder tumor samples. Clin Chem 2000;46:1555-1561. (Pubitemid 30776619)
11. Wang YA, Johnson SK, Brown BL, et al. Enhanced anticancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status. Int J Cancer 2008;123:1536-1544.
12. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-899. (Pubitemid 20192074)
13. Mathiasen IS, Lademann U, Jaattela M. Apoptosis induced by vitaminDcompounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 1999;59:4848-4856. (Pubitemid 29472887)
14. Schafer JM, Lee ES, O'Regan RM, Yao K, Jordan VC. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin Cancer Res 2000;6: 4373-4380. (Pubitemid 30840191)
15. Murphy PJ, Galigniana MD, Morishima Y, et al. Pifithrinalpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation. J Biol Chem 2004;279:30195-30201. (Pubitemid 38937944)
16. Toillon RA, Chopin V, Jouy N, Fauquette W, Boilly B, Le Bourhis X. Normal breast epithelial cells induce p53-dependent apoptosis and p53-independent cell cycle arrest of breast cancer cells. Breast Cancer Res Treat 2002;71:269-280. (Pubitemid 34263990)
17. Lazaro-Trueba I, Arias C, Silva A. Double bolt regulation of Rad51 by p53:Arole for transcriptional repression. Cell Cycle 2006;5:1062-1065. (Pubitemid 43765300)
18. Yoon D, Wang Y, Stapleford K, Wiesmuller L, Chen J. p53 inhibits strand exchange and replication fork regression promoted by human Rad51. J Mol Biol 2004;336:639-654. (Pubitemid 38183019)
19. Yun S, Lie ACC, Porter AC. Discriminatory suppression of homologous recombination by p53. Nucleic Acids Res 2004;32:6479-6489. (Pubitemid 40220359)
20. HonmaM, Momose M, Tanabe H, et al. Requirement of wildtype p53 protein for maintenance of chromosomal integrity. Mol Carcinog 2000;28:203-214. (Pubitemid 30672489)
21. Linke SP, Sengupta S, Khabie N, et al. p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res 2003;63:2596-2605. (Pubitemid 36605201)
22. Saintigny Y, Bertrand P, Lopez BS. Direct role of p53 on homologous recombination. Med Sci (Paris) 2005;21:43-48. (Pubitemid 40138205)
23. Miller KA, Sawicka D, Barsky D, Albala JS. Domain mapping of the Rad51 paralog protein complexes. Nucleic Acids Res 2004;32:169-178. (Pubitemid 38228616)
24. Liu N, Schild D, Thelen MP, Thompson LH. Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells. Nucleic Acids Res 2002;30:1009-1015. (Pubitemid 34679670)